

## [Hydroxychloroquine](#)

Essential medicine status

Section:

[29. Medicines for diseases of joints 29.2. Disease-modifying anti-rheumatic drugs \(DMARDs\)](#)

ATC codes: [P01BA02](#)

EMLc

Indication

Systemic lupus erythematosus ICD11 code: [4A40.0Z](#)

INN

Hydroxychloroquine

Medicine type

Chemical agent

List type

Complementary

Formulations

**Oral > Solid:** 200 mg (as sulfate)

EML status history

First added in 2011 ([TRS 965](#))

Changed in 2021 ([TRS 1035](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Hydroxychloroquine](#)

DrugBank

[Hydroxychloroquine](#)

Summary of evidence and Expert Committee recommendations

The Expert Committee recommended inclusion of hydroxychloroquine on the complementary list of the EML for the treatment of adults with systemic lupus erythematosus, given its beneficial effects in this condition. (Refer to the 2021 recommendation for hydroxychloroquine for the treatment of cutaneous lupus erythematosus).